Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05549414
Other study ID # PC001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 30, 2023
Est. completion date February 2026

Study information

Verified date March 2023
Source P-Cure
Contact Irena Barsky
Phone 0534304994
Email irab@hadassah.org.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent, previously irradiated thoracic cancer indicated for re- irradiation. ARM2: Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation. ARM3: Patients with unresectable pancreatic cancer. The primary objectives of the study for all arms are: 1. to describe the efficacy (local control after 3 month) and acute toxicity for patients treated with a fully-integrated CBGS and (2) to compare treatment plans between the fully-integrated CBGS and Photon therapy defined for each patient, based upon OAR sparing for comparable target coverage.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 2026
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Pathologically (histologically or cytologically) proven malignancy - Treatment planning analysis shows advantage to proton over photon treatments - both malignancies (such as thoracic tumors) as well as metastatic lesions (such as metastatic breast cancer or colorectal cancer to the lungs) are allowed - Patient must have CT confirmation of the tumor - Patients must have a life expectancy of > 6 months - Patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least 10 mm on CT imaging). - Patients must be a candidate for definitive radiation dose - There are no limits on prior therapy. Patients are allowed to have prior chemotherapy and surgery. Patients are allowed to have concurrent chemotherapy with radiation treatment. Patients are allowed to have chemotherapy or surgery after radiation treatment Exclusion Criteria: 1. Severe, active co-morbidity, defined as follows: 1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months 2. Transmural myocardial infarction within the last 6 months 3. Chronic obstructive pulmonary disease exacerbation or other respiratory illness other than the diagnosed lung cancer requiring hospitalization or precluding study therapy within 30 days before registration 4. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition (protocol may be significantly immunosuppressive endangering AIDS patients) 2. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception 3. Patients with life expectancy < 6 months 4. Patients that participate in another, active clinical trial carried out concurrently with this protocol

Study Design


Intervention

Device:
Proton Radiation
Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios

Locations

Country Name City State
Israel Hadassah Ein Karem Jerusalem

Sponsors (2)

Lead Sponsor Collaborator
P-Cure Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local Control The duration of local control will be measured from the start date of protocol radiation until the date of progressive disease. Local control will be determined based on RECIST Criteria Version 1.1. 3 months
Primary Acute Toxicity Incidence of treatment-related grade 3-5 adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 3 months
Primary Treatment Plan Comparison between Chair Based Proton System and Photon therapy Analysis and comparison of dose volume histograms (DVHs) and isodoses for each modality 3 months
Secondary Progression Free Survival The time from study registration until the first occurrence of local, regional, or distant progression, or death from any cause, or until last follow-up 2 years
Secondary Overall Survival The time from study registration until death or last follow-up 2 years
Secondary Long-term Toxicity Incidence of treatment-related grade 3-5 adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 2 Years
Secondary Quality of Life Lung Cancer Patients: FACT-Lung and EQ-5D Head and Neck Patients: EORTC QLQ-C30 and the EORTC QLQ-H&N35 Pancreas Patients: Quality of Life assessment using Patient Reported Outcomes 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05023434 - A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Completed NCT04114786 - 3D Printed Mask for GBM and Brain Mets N/A
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT02911155 - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Completed NCT02852655 - A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Phase 1
Completed NCT00329589 - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients Phase 1
Completed NCT01650922 - Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples N/A
Completed NCT00505141 - Urban Environmental Exposures and Childhood Cancer N/A
Completed NCT00504660 - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Phase 2
Completed NCT00979810 - Image-Guided Stereotactic Biopsy of High Grade Gliomas N/A
Recruiting NCT04899908 - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Phase 2
Active, not recruiting NCT02851706 - Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Completed NCT01012609 - External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Phase 2
Completed NCT00782756 - Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma Phase 2
Terminated NCT03149575 - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Phase 3
Completed NCT01974804 - Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
Withdrawn NCT01320787 - 18-F-Fluoroacetate as PET Imaging Agent Phase 1